Investigators Set to Explore Selinexor Monotherapy or Plus R

Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Related Keywords

Johno Mascarenhas , , Dynamic International Prognostic Scoring System , Adult Leukemia Program , Tisch Cancer Institute , Myeloproliferative Disorders Program , Icahn School Of Medicine At Mount Sinai , Icahn School , Mount Sinai , Blood Cancers , Myeloid Disorders , Myeloproliferative Disorders , Myelofibrosis Symptom Assessment Form , Adv Hematol , Selinexor , Jak Inhibitor Naive Myelofibrosis , Ruxolitinib , Mpns , Xport Mf 044 , Xport Mf 034 , Xpo1 Inhibitor ,